The 3rd Paris NASH Symposium occurred on July 6-7, 2017 at the Institut Pasteur in Paris, France.
Presentations from this symposium can be accessed below, or at the conference webpage: http://www.paris-nash-symposium.org/
THURSDAY, JULY 6, 2017
- Welcome Remarks
Lawrence Serfaty (FR) - Inauguration Address
Stanislas Pol (FR)
SESSION 1 • NASH IN OTHER SETTINGS
Chairs: Arun Sanyal (US) and Patrick Marcellin (FR)
- NASH in HIV: how big is the problem?
Maud Lemoine (UK) - Are the therapeutic targets for NASH in HIV the same as in garden-variety NASH?
Richard Sterling (US) - The burden of NASH before and after liver transplantation
Rajender Reddy (US) - Is NASH responsible for disease progression after SVR in subjects with HCV?
Lawrence Serfaty (FR)
SESSION 2 • GETTING TO THE HEART OF THE MATTER
Chairs: Bruno Vergès (FR) and Ariel Cohen (FR)
- Atherogenic risk factors and cardiac outcomes in NASH
Raluca Pais (FR) - NASH and the myocardium
Mohammad Siddiqui (US) - QTc and NASH-from molecular biology to clinical significance
Franck Boccara (FR)
SESSION 3 • CLINICAL HOT TOPICS
Chairs: Mohammad Siddiqui (US) and Philippe Mathurin (FR)
- Disease burden report for Europe
Homie Razavi (US) - Prospective assessment of disease evolution in NASH
Arun Sanyal (US) - DILI phenotypes and its assessment in NASH
Robert Fontana (US)
SESSION 4 • THE ROLE OF THE GUT IN NASH
Chairs: Lawrence Serfaty (FR) and Gyongyi Szabo (US)
- Plasticity of the mucosal barrier: Insights into regulation of the Intestinal Epithelial Barrier and Steatohepatitis
Asma Nusrat (US) - Endocrine signaling from the gut and its implications for NASH
Bart Staels (FR) - Impact of macronutrient constituents of diet on NASH phenotype and outcomes
Jean-Francois Dufour (CH) - Diet-microbiome interactions and NASH
Puneet Puri (US)
SESSION 5 • INFLAMMATION
Chairs: Alexandre Louvet (FR) and Stanislas Pol (FR)
- Gut derived activators of inflammation in NASH
Gyongyi Szabo (US) - Intrahepatic intracellular activators of innate immunity in NASH
Wajahat Mehal (US) - Role of macrophages in disease development and progression
Frank Tacke (DE) - Adipose tissue inflammation in type 2 diabetes and NASH
Karine Clement (FR)
SESSION 6 • TECHNOLOGIC INNOVATIONS IN NASH
Chairs: Rohit Loomba (US) and Jean-Pierre Bronowicki (FR)
- Hijacking the microbiome to modify NASH
Dean Falb (US) - Endoscopic treatment of Diabetes and NASH
Harith Rajagopalan (US) - Nanoparticle based anti-fibrotic therapies in NASH
Wenbin Ying (US) - The Copper - NAFLD connection: Role of hepatic copper deficiency
Peter Ferenci (AT)
FRIDAY, JULY 7, 2017
SESSION 7 • INNOVATIONS IN FIBROSIS ASSESSMENT
Chairs: Pierre Bedossa (FR) and Scott Friedman (US)
- New algorithms for assessment of fibrosis in NAFLD
Jérôme Boursier (FR) - Dual photon microscopy and its potential for assessing fibrosis evolution
Arun Sanyal (US) - Potential role of deuterated markers in assessment of fibrosis
Rohit Loomba (US) - Assessing fibrosis using antibodies to collagen epitopes
Morten Karsdal (DK)
SESSION 8 • SHORTENING TIMELINES AND IMPROVING EFFICIENCY IN DRUG DEVELOPMENT
Chairs: Mark DeLegge (US) and Dominique Larrey (FR)
- Seamless drug development paradigms
Claudia Filozof (UK) - Point of Care tests for the diagnosis of NASH in clinical trials, design consideration and potential use
Karine Lacombe (FR) - Causality assessment in large data: potential applications for NASH
Antoine Chambaz (FR)
SESSION 9 • REGULATORY LANDSCAPE
Chair: Lawrence Serfaty (FR)
- What is new on the regulatory front?
Veronica Miller (US)
WORKING LUNCHES SESSION
- GROUP 1: Transatlantic Biomarker Development
Julia Brosnan (US) and Sudha Shankar (US) - GROUP 2: NASH cohorts for clinical trials around the world
Arun Sanyal (US) and Vlad Ratziu (FR) - GROUP 3: The place of bariatric surgery in NASH: can we extend the indications?
Philippe Mathurin (FR) and Nicolas Goossens (CH)
SESSION 10 • STATE OF THE ART LECTURE
Chair: Arun Sanyal (US)
- Past, present and future of therapeutics for liver fibrosis
Scott Friedman (US) - Closing Remarks
Arun Sanyal (US)
